SIN1, a critical component of the mTOR-Rictor complex, is overexpressed and associated with AKT activation in medullary and aggressive papillary thyroid carcinomas

Surgery (United States)

Volumn 156, Issue 6, 2014, Pages 1542-1549

  Moraitis, Dimitrios ^a   Karanikou, Maria ^b   Liakou, Chryssa ^b   Dimas, Konstantinos ^c   Tzimas, George ^a   Tseleni Balafouta, Sofia ^b   Patsouris, Efstratios ^b   Rassidakis, George Z ^b,d   Kouvaraki, Maria A ^a,d  

^a HYGEIA HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PROTEIN KINASE B; PROTEIN P55; PROTEIN P76; STRESS ACTIVATED PROTEIN KINASE INTERACTING PROTEIN 1; SYNAPSIN I; UNCLASSIFIED DRUG; MAPKAP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; ONCOPROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; GENE OVEREXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MEDULLARY THYROID CARCINOMA CELL; PAPILLARY THYROID CARCINOMA CELL; POORLY DIFFERENTIATED THYROID CANCER; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; THYROID CANCER CELL LINE; THYROID FOLLICULAR CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMORIGENESIS; WESTERN BLOTTING; CARCINOMA; COMPARATIVE STUDY; EPIDEMIOLOGY; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; NEEDLE BIOPSY; PATHOLOGY; SENSITIVITY AND SPECIFICITY; THYROID TUMOR; TRANSCRIPTION INITIATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; BIOPSY, NEEDLE; BLOTTING, WESTERN; CARCINOMA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; ONCOGENE PROTEIN V-AKT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOR SERINE-THREONINE KINASES; TRANSCRIPTIONAL ACTIVATION;

EID: 84922418281     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2014.08.095     Document Type: Article

References (25)

1. Tubiana M, Schlumberger M, Rougier P, Laplanche A, Benhamou E, Gardet P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985;55: 794-804.
2. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97: 418-28.
3. Kouvaraki MA, Shapiro SE, Lee JE, Evans DB, Perrier ND. Surgical management of thyroid carcinoma. J Natl Compr Canc Netw 2005;3: 458-66.
4. Kouvaraki MA, Lee JE, Shapiro SE, Sherman SI, Evans DB. Preventable reoperations for persistent and recurrent papillary thyroid carcinoma. Surgery 2004;136: 1183-91.
5. Simon D, Goretzki PE, Witte J, Roher HD. Incidence of regional recurrence guiding radicality in differentiated thyroid carcinoma. World J Surg 1996;20: 860-6; discussion 866.
6. Hay ID, Grant CS, Bergstralh EJ, Thompson GB, van Heerden JA, Goellner JR. Unilateral total lobectomy: Is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma? Surgery 1998;124: 958-64; discussion 964-6.
7. Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of thyroid. Ann Surg Oncol 1996;3: 534-8.
8. Yeager N, Brewer C, Cai KQ, Xu XX, Di Cristofano A. Mammalian target of rapamycin is the key effector of phosphatidylinositol- 3-OHinitiated proliferative signals in the thyroid follicular epithelium. Cancer Res 2008;68: 444-9.
9. Wang S, Lloyd RV, Hutzler MJ, Rosenwald IB, Safran MS, Patwardhan NA, et al. Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma. Thyroid 2001;11: 1101-7.
10. Furuya F, Lu C, Willingham MC, Cheng SY. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. Carcinogenesis 2007;28: 2451-8.
11. Jin N, Jiang T, Rosen DM, Nelkin BD, Ball DW. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. J Clin Endocrinol Metab 2009;94: 4107-12.
12. Zoncu R, Efeyan A, Sabatini DM. mTOR: From growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011;12: 21-35.
13. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, et al. mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s. Curr Biol 2006;16: 1865-70.
14. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006;127: 125-37.
15. Kouvaraki MA, Liakou C, Paraschi A, Dimas K, Patsouris E, Tseleni-Balafouta S, et al. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas. Surgery 2011;150: 1258-65.
16. The NCCN Clinical Practice Guidelines in Oncology. Thyroid Carcinoma (Version 1.2011). National Comprehensive Cancer Network; 2011. Available from: Https://www.nccn. org/store/login/login.aspx?ReturnURL=http://www.nccn. org/professionals/physician-gls/pdf/thyroid.pdf.
17. Inamdar KV, Romaguera JE, Drakos E, Knoblock RJ, Garcia M, Leventaki V, et al. Expression of eukaryotic initiation factor 4E predicts clinical outcome in patients with mantle cell lymphoma treated with hyper-CVAD and rituximab, alternating with rituximab, high-dose methotrexate, and cytarabine. Cancer 2009;115: 4727-36.
18. Vega F, Medeiros LJ, Leventaki V, Atwell C, Cho-Vega JH, Tian L, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006;66: 6589-97.
19. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004;18: 1926-45.
20. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005;307: 1098-101.
21. Faustino A, Couto JP, Populo H, Rocha AS, Pardal F, Cameselle-Teijeiro JM, et al. mTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 2012;97: E1139-49.
22. Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol 2011;7: 569-80.
23. Saji M, Narahara K, McCarty SK, Vasko VV, La Perle KM, Porter K, et al. Akt1 deficiency delays tumor progression, vascular invasion, and distant metastasis in a murine model of thyroid cancer. Oncogene 2011;30: 4307-15.
24. Liu P, Guo J, Gan W, Wei W. Dual phosphorylation of Sin1 at T86 and T398 negatively regulates mTORC2 complex integrity and activity. Protein Cell 2014;5: 171-7.
25. Pilotti S, Collini P, Rilke F, Cattoretti G, Del Bo R, Pierotti MA. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994;172: 337-42.